Preclinical and clinical studies suggest that MYC-high SCLC tumors exhibit selective sensitivity to Aurora kinase A/B (AURKA/AURKB) inhibitors, such as alisertib or barasertib, which impair MYC-driven tumor growth [22,77,78]. The gene discussed is MYC; the disease is neoplasm.